DMII Stock Forecast: Drugs Made In America Acquisition II Corp. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 1 Aug 2026 — in the weakest quartile.
DMII stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Drugs Made In America Acquisition II Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (74): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (8): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
The rank is the raw material. Whether the rules would actually own Drugs Made In America Acquisition II Corp. — and when they’d sell — is the membership.
DMII stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on DMII, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
DMII analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Drugs Made In America Acquisition II Corp. (DMII) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 77.8×
- Price / sales
- —
- Price / book
- 1.3×
- EV / EBITDA
- −347.4×
Cheaper than 9% of US stocks
Cheaper than 63% of US stocks
Cheaper than 98% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- 0.9%
- Return on assets
- 0.8%
- Dividend yield
- —
Higher than 45% of US stocks
Higher than 48% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
DMII vs competitors
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| DMIIDrugs Made In America Acquisition II Corp. | $644.0M | 24 |
| EVACEQV Ventures Acquisition Corp. II | $604.7M | 25 |
| BCSSBain Capital GSS Investment Corp. | $596.8M | 25 |
| CXIIChurchill Capital Corp. XII | $588.8M | 5 |
| CEPFCantor Equity Partners IV, Inc. | $572.5M | 24 |
| CCXIChurchill Capital Corp. XI | $772.0M | 9 |
| AEXAAmerican Exceptionalism Acquisition Corp. A | $558.4M | 8 |
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DMII appears on the weeks it earns a place.
Frequently asked questions about DMII stock
How does Ticker Nerd's model rank DMII?
As at 1 Aug 2026, Drugs Made In America Acquisition II Corp. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (74 of 100).
What is the DMII stock forecast for 2030?
No analyst covering Drugs Made In America Acquisition II Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DMII are extrapolating price history, which says nothing about the business.
What does Drugs Made In America Acquisition II Corp. do?
Drugs Made In America Acquisition II Corp. is a special purpose acquisition company (SPAC) established in 2024 with the primary objective of effecting business combinations through mergers, share exchanges, asset acquisitions, or similar transactions.
About Drugs Made In America Acquisition II Corp.
Drugs Made In America Acquisition II Corp. is a special purpose acquisition company (SPAC) established in 2024 with the primary objective of effecting business combinations through mergers, share exchanges, asset acquisitions, or similar transactions. The company targets the pharmaceutical industry, aiming to identify and acquire businesses that contribute to reducing U.S. dependence on foreign pharmaceutical manufacturing. By focusing on domestic production and advanced manufacturing technologies for critical drugs, it seeks to help strengthen the American medical supply chain. Incorporated as an exempted company in the Cayman Islands and headquartered in Fort Lauderdale, Florida, the company completed its initial public offering in 2025, raising $500 million. Its structure allows holders of its units to trade ordinary shares and rights separately, enhancing liquidity. This blank check company plays a strategic role as a financial vehicle facilitating investments that support onshoring critical pharmaceutical manufacturing capabilities within the United States.
CEO Ms. Lynn Stockwell · United States